Combined with chemotherapy in the treatment of ovarian cancer is the preferred method

New York University, Dr. Franco Muggia, two chemotherapy drugs - paclitaxel and cisplatin combination in the treatment of advanced ovarian cancer with high doses in one of the same drug efficacy, but almost no serious side effects. A separate study found that the use of cisplatin in combination with several drugs have the same effect, but the use of high-dose cisplatin, in patients with difficult to bear. More than 80 percent of advanced ovarian cancer patients are able to complete the merger of six courses of chemotherapy. Only 69% of the use of high-dose cisplatin for the treatment of patients and 71 percent of the use of large doses of paclitaxel can be completed in six treatment. Receive the best treatment of cisplatin. In contrast, 67 percent of cisplatin or combined treatment of patients with a response, only 42% of the only patients treated with Taxol reaction.
In addition, to accept any of cisplatin with the treatment of patients with complete remission of their cancer risk is acceptable only in patients with Taxol treatment twice. Accept cisplatin in the treatment of patients with the mortality rate is also lower. Compared to treatment with cisplatin, Taxol-treated patients receive an average mortality rate higher than 15%, lower than its combined treatment of one percent. Compared with the merger of chemotherapy, cisplatin and Taxol treatment has significant side effects.
Easy to accept cisplatin in the treatment of a gastrointestinal, kidney and nerve disease Bose Taxol treatment prone to low leukocyte index and fever. Compared with paclitaxel, cisplatin or cisplatin and other drugs combined effect of better. In the three treatment methods in overall survival rates are similar. The merger because the toxicity of chemotherapy smaller, so the merger is still the preferred treatment of treatment programmes.